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Abstract
Spinal muscular atrophy (SMA) is a neuromuscular disease caused by mutations in survival motor neuron 1 (SMN1).
SMN-restoring therapies have recently emerged; however, preclinical and clinical studies revealed a limited therapeutic
time window and systemic aspects of the disease. This raises a fundamental question of whether SMA has presymptomatic,
developmental components to disease pathogenesis. We have addressed this by combining micro-computed tomography
(μCT) and comparative proteomics to examine systemic pre-symptomatic changes in a prenatal mouse model of SMA.
Quantitative μCT analyses revealed that SMA embryos were significantly smaller than littermate controls, indicative of
general developmental delay. More specifically, cardiac ventricles were smaller in SMA hearts, whilst liver and brain
remained unaffected. In order to explore the molecular consequences of SMN depletion during development, we generated
comprehensive, high-resolution, proteomic profiles of neuronal and non-neuronal organs in SMA mouse embryos.
Significant molecular perturbations were observed in all organs examined, highlighting tissue-specific prenatal molecular
phenotypes in SMA. Together, our data demonstrate considerable systemic changes at an early, presymptomatic stage in
SMA mice, revealing a significant developmental component to SMA pathogenesis.
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Introduction
Spinal muscular atrophy (SMA) is the second most common
autosomal recessive disorder in humans, after cystic fibrosis:
with 2% of people carrying an SMA-associated mutation, this
disease affects 1 in 6000–10 000 live births and is the leading
genetic cause of infant death (1,2). SMA is primarily a neurode-
generative disease characterized by loss of lower motor neurons
and muscle atrophy (3–5). In 98% of cases, SMA arises from a
homozygous mutation in the survival motor neuron 1 gene (SMN1)
(6), leading to insufficient production of full-length SMN protein.
SMN is ubiquitously expressed in all cell types, including during
development and is crucial for survival (7,8). Mouse embryos
in which Smn has been genetically knocked out die around the
peri-implantation stage (9).
In late 2016, Spinraza® (nusinersen) became the first FDA-
approved drug to treat SMA (5,10–14). The FDA subsequently
approved Zolgensma® (onasemnogene abeparvovec-xioi) in
May 2019 (15,16). Both of these treatments work by increasing
the levels of full-length SMN protein, the former through an
antisense oligonucleotide and the latter using AAV9-delivered
gene replacement therapy. However, despite the success of both
Spinraza® and Zolgensma® in improving outcomes in SMA
patients, their efficacy is highly variable from one patient to
another, and they modify disease course rather than providing
a cure (10,15,16).
One likely explanation for the modest efficacy of Spinraza®
and Zolgensma® in some patients is the timing and targeting of
therapy delivery. Thus, results from clinical trials suggest that
treatment should be performed as early as possible to obtain
maximal therapeutic benefit (10,17). This finding is supported by
pre-clinical animal studies, which have revealed a narrow post-
natal time window for the successful restoration of SMN in SMA
mice (18–20). Moreover, several lines of evidence suggest that
systemic delivery of therapies, rather than targeting of motor
neurons in the spinal cord, is required for maximal therapeutic
benefit (21–23).
Despite our growing awareness of the need for early thera-
peutic intervention in SMA, we still do not know where and when
the disease first manifests. The majority of pre-clinical studies
have been performed in post-natal animals. However, several
studies support the hypothesis that SMA, particularly in its
most severe forms, may present with pre-symptomatic, prenatal
developmental phenotypes (24–27). To address this important
issue, we have undertaken a comprehensive morphological and
proteomic characterization of systemic features of SMA at a
pre-symptomatic, prenatal stage in the Taiwanese mouse model
of severe SMA. We report the presence of morphological and
molecular changes across multiple tissues and organs at E14.5,
thereby revealing significant pre-symptomatic developmental
phenotypes in SMA, and provide access to freely available mor-
phological and molecular datasets of SMA embryos that can be
utilized for further research.
Results
Most studies on pre-symptomatic SMA in the Taiwanese mouse
model have focused on postnatal phenotypes. Here, we inves-
tigated disease manifestation during embryonic development
at E14.5, approximately 13 days prior to overt neuromuscu-
lar symptom development. To better understand the systemic
nature of disease at this time point of development, we exam-
ined a range of organs, including the brain, spinal cord, liver,
heart and skeletal muscle.
SMA mouse embryos are smaller than littermate
controls
We first asked whether anatomical defects could be detected
in SMA embryos compared to littermate controls. To do so, we
performed micro-computed tomography (μCT) imaging of whole
embryos from a single litter of mice at E14.5 (Fig. 1A, i-iv). Initial
anatomical, qualitative assessment of the embryos confirmed
the presence and standard location of all major body organs and
systems in both SMA and littermate animals. Using the scans,
we then segmented the images to facilitate volumetric mea-
surement and 3D reconstruction of regions of interest (Supple-
mentary Material, Movie 1). We measured the volumes of whole
embryos as well as brain, liver and the cardiac ventricles (Fig. 1B,
Supplementary Material, Movies 2–5). Volumetric quantification
revealed that SMA embryos were significantly smaller than their
littermate controls (Fig. 1C; unpaired t-test, n = 4, P = 0.0396). Vol-
ume measurements of liver and brain revealed no difference
between SMA and control embryos, whereas the cardiac ven-
tricles were significantly smaller in the SMA animals (Fig. 1C;
unpaired t-test, n = 4, P = 0.0059). Taken together, these experi-
ments showed that SMA embryos differ from controls in total
body size, suggesting a developmental delay in SMA embryos
compared to littermate controls, and that internal organs are
differentially affected.
Cardiac ventricles do not show overt pathology
As cardiac ventricles were found to be significantly smaller in
SMA mice (Fig. 1C), we next examined whether they exhibited
any structural changes known to be representative of cardiac
pathology, and which are known to occur in the heart of SMA
mice at later developmental stages. For example, Shababi et al.
(28) described thinning of the interventricular septum (IVS) in
the E17.5 heart of SMA embryos of the same model. Using
orientation-adjusted transverse μCT images, we performed mor-
phometric measurements of the ventricles. We examined the
width of the IVS and thickness of the left ventricular wall.
Despite the smaller volume of SMA hearts at E14.5, no overt
structural defects were identified (Fig. 2A, A’, C and D). To verify
this finding, we performed the same measurements on H&E-
stained transverse cryosections. Again, structural defects were
not observed in the heart (Fig. 2B, B’, C and D), suggesting the
presence of a developmental delay, rather than overt cardiac
pathology, at this stage of embryonic development.
Mass spectrometry reveals widespread proteomic
changes
Having identified developmental differences between SMA and
control embryos in mice at the morphological level, we next
sought to establish whether developmental defects resulting
from SMN depletion were occurring at a molecular level. Func-
tionally, SMN is known to play key roles in regulating both
transcription, where it participates in small nuclear ribonucle-
oprotein formation and is a component of the spliceosome (29),
and translation (30). For this reason, we performed a proteomics
screen to examine molecular differences at the level of the
proteome, in preference to using RNA sequencing or microarray.
For quantitative and comparative analyses, pooled samples of
E14.5 brains, spinal cords, livers, hearts and skeletal abdominal
muscles were processed by 10-plex tandem mass tagging (TMT)
mass spectrometry (Fig. 3A).
Quality-checked (see Methods) identified proteins and
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Figure 1. Anatomical differences in SMA mouse embryos at E14.5 revealed using μCT scans. (A) Representative 3D views of a control embryo from μCT scans: (i)
coronal, (ii) sagittal, (iii) transverse, (iv) surface-rendered, scale bars = 2 mm. (B) Transverse images representative of the manual segmentation performed for each
organ (outlined in blue), pink boxes show the corresponding sagittal view, scale bars = 1 mm. The far-right column shows surface rendering of the computed volumes
for each region of interest, scale bars = 2 mm. (C) Volumetric data represented as a bar chart (mean, SD, n = 4 per genotype, ∗P < 0.05, ∗∗P < 0.01, unpaired t-test).
by two or more unique peptides. The ratios of SMA versus control
abundance for each protein in every tissue were calculated
and used as input for subsequent bioinformatic analysis using
ingenuity pathway analysis (IPA). Out of a total of 7185 inputted
ratios, the software returned 6701 mapped protein identifi-
cations. For additional stringency, all further analyses were
performed only on these mapped IDs returned by IPA. A cut-
off of 20%-fold change relative to controls (expressed as fold
change of +1.2 or −1.2) was used to determine differentially-
expressed proteins in SMA organs compared to controls. These
analyses revealed widespread disruption to the proteome in
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Figure 2. Absence of overt pathological defects in cardiac ventricles of SMA mouse embryos. (A,A’) Representative orientation-adjusted transverse μCT scans used for
morphometric measurements. (B,B’) Representative HE-stained transverse cryosections used for morphometric measurements. IVS = interventricular septum, RV = right
ventricle, LV = left ventricle, RA = right atrium, LA = left atrium, scale bars = 1 mm. (C) and (D) Morphometric data presented as bar charts showing no changes in
morphological parameters previously used to identify degenerative cardiac pathology at later stages of SMA (SD, n = 4 per genotype for μCT data, n = 3 per genotype for
cryosections, ∗P < 0.05, unpaired t-test).
of low levels of SMN at this stage of embryonic development
(Fig. 3B, Supplementary Material, Table S1). Of all organs
examined, the liver had the highest number of differentially-
expressed proteins (1753) in SMA mice. Assessment of proteome
differences across all organs revealed that the majority of
proteins were downregulated, rather than upregulated, in SMA
tissues (Supplementary Material, Table S1, Figure 3B).
Changes in the proteome are organ specific
To examine the extent to which proteomic changes occurring
downstream of low SMN levels were shared or divergent between
different tissues and organs, we then determined the extent of
overlap of proteome changes across combinations of two, three,
four or all five organs studied (Fig. 3C and D). Brain and spinal
cord shared the highest similarity of regulated proteins (13.7%),
as might be expected given their similar cellular composition.
However, in all of the other combinations of organs examined,
the extent of overlap between proteomic changes was less than
10% (Fig. 3C). For example, a comparison of the SMN-modified
proteome between spinal cord and heart showed only an 8.4%
overlap. Likewise, comparison of the SMN-modified proteome
between skeletal muscle and heart revealed a 6.1% overlap. In
total, only 0.1% of proteomic changes downstream of SMN were
conserved across all five organs and tissues examined (Fig. 3C).
When considering the absolute numbers of overlapping pro-
teins, only three individual proteins (GEMIN8, DDX20/GEMIN3
and HPS4) were significantly modified across all tissues and
organs examined (Fig. 3D, Supplementary Material, Table S2).
GEMIN8 and DDX20 are known SMN interactors, thereby provid-
ing internal controls to validate the proteomics data (31,32).
Although the pattern of developmental molecular disruption
was heterogeneous between organs and tissues in SMA mouse
embryos at the level of individual proteins, it remained possible
that similar cellular pathways were being affected. Therefore, to
gain a better understanding of the functional consequences of
low levels of SMN, we used IPA to identify canonical pathways
that were affected in each organ (see Materials and Methods and
Supplementary Material, Table S3).
Important pathways for embryonic development were
amongst the most affected ones in each organ, such as ephrin
receptor signalling in the liver and PFKFB4 (6-phosphofructo-
2-kinase/fructose-2,6-biphosphatase 4) signalling in the spinal
cord, with a -log(P-value) of 10.2 and 3.16, respectively
(Supplementary Material, Table S3). However, when we selected
the top 100 most affected canonical pathways in the spinal
cord and searched for similar pathway changes across the other
organs and tissues, there was very little overlap. Thus, no identi-
fied canonical pathway was affected by the same magnitude
across all five organs (Fig. 4A and Supplementary Material,
Table S2). Heatmaps anchored to the top 100 affected canonical
pathways of the other four organs further demonstrated the lack
of commonality between affected pathways (Supplementary
Material, Figure S1). Taken together, these detailed comparative
proteomic analyses revealed a striking lack of overlap between
the number or identity of dysregulated proteins and disrupted
canonical pathways between distinct tissues and organs. Thus,
these data demonstrate that at E14.5, SMN insufficiency causes a
wide range of downstream molecular defects, which are highly
organ specific. As a result, it may not always be possible to
predict the molecular consequences of SMN depletion in one
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Figure 3. TMT mass spectrometry revealed widespread, organ-specific changes in the proteome of SMA mouse embryos at E14.5. (A) Schematic representation of
sample processing and experimental pipeline for the proteomics screen, Ctl stands for Control embryos. (B) Dotplot of all protein IDs mapped in IPA for each organ
of interest. Dotted blue lines show the 20% up- and down-regulated threshold. (C) Bar chart showing the percentage of overlapping protein IDs dysregulated by 20%
or more for every possible combination of organs. The horizontal bar chart shows the size of each set of dysregulated proteins used to identify overlaps. (D) Bar chart
showing the absolute number of overlapping protein IDs dysregulated by 20% or more for every combination of organs possible.
Of particular relevance to SMA, RhoA signalling was
identified in the canonical pathway analysis performed by IPA
(33). Again, individual organs were affected differently: brain,
spinal cord and heart only had one, three and two dysregulated
proteins associated with the pathway, respectively. In contrast,
the liver had 25 and the muscle had nine dysregulated proteins,
corresponding to P-values of 6.761E-06 and 5.012E-05 for protein
enrichment (Fig. 4B). Similarly, actin cytoskeleton signalling,
also identified by IPA, was significantly disrupted in the liver
(P-value of 3.090E-08 and 44 proteins) and skeletal muscle
(P-value of 2.188E-05 for 13 proteins), but with only a few
annotated proteins in the spinal cord and heart (Fig. 4B). To
explore this further, we used The Database for Annotation,
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Figure 4. Organ/tissue-specific SMN expression and molecular pathway disruption. (A) Heatmap anchored on the top 100 affected canonical pathways of the spinal
cord (according to -log(P-value) for each pathway identified), as generated by IPA. Pathways for which P-values could not be calculated in given organs are shown in grey.
Note the lack of consistency of changes across each of the different tissues/organs. (B) Protein count and P-values (Fisher’s exact test, P∗ < 0.05 shown in bold) reported
by IPA for enrichment of the RhoA and Actin Cytoskeleton signalling pathways in each organ of interest. (C) Gene ontology enrichment analysis reported by DAVID
for the term ‘cytoskeleton’ (Fisher’s exact test, significance reached for Benjamini-adjusted P < 0.05, shown in bold). (D) Western blot for SMN on pools of embryonic
organs used for mass spectrometry (n = 5 per genotype). (E) Bar chart representing the quantification of the above western blot. SMN protein levels were normalized to
total protein stain signal for each lane.
functional annotation of the differentially-expressed proteins
from each organ. The term ‘cytoskeleton’ was prevalent in the
gene ontology enrichment analysis of all organs apart from the
brain, which reflects its overall low number of dysregulated
proteins (Fig. 4C).
SMN protein levels do not correspond to the number
of dysregulated proteins
To determine the extent to which organ-specific responses in
SMA may result from differing absolute levels of SMN protein
between tissues and organs, we compared SMN levels across
each of the organs in our study using quantitative western blot
(34,35). SMN protein levels were measured in embryonic samples
pooled from the original protein extracts used for mass spec-
trometry in order to allow direct correlative comparison of find-
ings (Fig. 4D). The liver revealed the highest relative levels of SMN
protein in both control and SMA samples at E14.5 (Fig. 4E). SMN
levels present in control livers suggests that the liver requires
high amounts of SMN protein at this embryonic age and may
therefore explain, at least in part, the finding that it was the
most affected organ in our proteomic screen. However, there was
no relationship between the number of dysregulated proteins in
each organ and SMN levels in control animals, nor was there a
relationship between the number of dysregulated proteins and
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Supplementary Figure S2). Differences in SMN levels between the
different organs, control or SMA, are therefore unlikely to fully
explain the organ-specific effects highlighted by the proteomics
data, and rather suggest the presence of tissue/organ-specific
pathways that are regulated by SMN during development.
Discussion
In summary, we have generated novel, high-resolution pro-
teomics datasets from SMA mouse embryos, facilitating detailed
assessment of developmental aspects of the disease and
SMN biology. Besides revealing the tissue-specific nature of
SMN depletion during development, these datasets provide
further support for a role for cytoskeletal dysregulation and
the RhoA/ROCK signalling pathway in SMA (33,36,37). Of note, a
recent paper by Siranosian et al. described changes in the actin
cytoskeleton regulation pathway in whole blood transcriptome
of adult SMA patients, confirming the systemic nature of
pathway dysregulation in SMA (38). Combining μCT with these
results, we present evidence suggesting that SMN depletion
leads to a range of morphological and molecular developmental
perturbations in SMA, manifesting in advance of the onset of
degenerative neuromuscular symptoms commonly associated
with the disease. It has long been known that SMN levels are
higher prenatally than postnatally (8,39). Our findings therefore
provide experimental support for the hypothesis that high levels
of SMN during development highlight a strong requirement
for the protein during prenatal stages of development and
may help to explain, at least in part, some of the systemic
alterations observed in SMA pathology (22). They also serve to
reinforce the need for detailed studies of systemic pathologies
in human patients, including those that are surviving for longer
periods due to the action of new SMN-restoring therapies
(5). Indeed, the magnitude of changes observed in the liver
during the present study highlights the potential importance
of this organ for understanding disease mechanisms and
modulation (40–42).
Considering the number of dysregulated proteins identified
in the liver, the finding that its volume was not significantly
affected in the E14.5 Taiwanese embryos may be, initially, sur-
prising. However, these results demonstrate that it is not possible
to predict the presence or absence of molecular perturbations
based solely on a morphological analysis of a tissue or organ,
and vice versa. Our findings therefore highlight the importance
of combining morphological and molecular assays to reveal the
true extent of developmental phenotypes in SMA.
Our results may have significant implications for preclinical
and clinical development and evaluation of therapies for SMA.
Our finding of early changes in the SMA embryos of the Tai-
wanese mouse model provides further evidence for the presence
and importance of an early therapeutic time window. Although
these findings require validation in other mouse models of
SMA, they extend our understanding of presymptomatic SMA.
Our results suggest that effective delivery of therapy will likely
require treatment in the presymptomatic phases of the disease,
during the perinatal, or perhaps even prenatal, period in human
patients (5,39,43). However, crucial ethical issues surround the
use of human in utero gene therapy as a treatment strategy.
Nevertheless, the heterogeneity of responses to SMN depletion
that we observed across different tissues and organs serves to
highlight the importance of careful systemic treatment delivery,
and the limitations that may be associated with focusing solely
on the neuromuscular system.
Materials and Methods
Experimental aims and design
This study was designed to determine the prenatal manifesta-
tions of Spinal Muscular Atrophy in the Taiwanese mouse model.
All data presented here were replicated in at least three mice,
with all volumetric and morphometric data quantified blinded
to genotypes. The proteomics screen was performed on pooled
samples coming from five embryos.
Animals
All animals were bred and handled following the UK Animals
(Scientific Procedures) Act, 1986. Procedures were approved by
the internal ethics committee at the University of Edinburgh and
following UK Home Office regulations. The Taiwanese model of
SMA was maintained as previously described and obtained from
Jackson Laboratories (strain 005058) (44). In the text, we refer
to Smn+/−;SMN2tg/0 embryos as controls, and Smn−/−;SMN2tg/0 as
SMA embryos. The morning of vaginal plug discovery following
timed mating was counted as E0.5. The pregnant dam was culled,
and the embryos collected when they reached the age of E14.5.
Anatomy
Micro-computed tomography. A single litter of embryos was dis-
sected at E14.5. Eight whole embryos (four controls and four
SMA) were fixed in 4% paraformaldehyde (PFA) for 3 days at
4◦C and then sent to the Experimental and Preclinical Imaging
Centre at Leeds University. There, the embryos were incubated
in 3 mL of Lugol’s (Sigma Aldrich, US) staining solution on a
roller at room temperature. The staining solution was changed
after 24 h. After 5 days, the embryos were embedded in 1%
agarose (Web Scientific) and scanned with SkyScan 1176 (Bruker,
Belgium) with the following parameters: 9 μm pixel size, 50 kV,
500 μA, 0.5 mm aluminium filter, exposure 1010 ms, rotation step
0.2◦, 4 averages, 180◦ scan. The data were reconstructed with
NRecon (Bruker) software using the Feldkamp algorithm with
the following parameters: smoothing: 4, ring artefact correction:
14, beam hardening correction: 40%.
Volume measurements. Using Horos software (version 3.3.5),
regions of interest (ROIs) were manually segmented in each
individual transverse section and volumes were subsequently
computed from these ROIs. All segmentation was performed
blinded to the genotype of the embryos. Movies were obtained
using the Movie Export tool (Supplementary Material, Movies
2–5).
Morphometric measurements of cardiac ventricles. Image orien-
tation was adjusted in 3D-view in Horos to make consistent
measurements across embryos. The transverse section chosen
for measurements corresponded to the plane crossing the apex
of the heart in sagittal view and perpendicular to the vertebral
column of the embryo. Each value for the width of the IVS or the
thickness of the left ventricular wall is the average length mea-
sured across the structure at three different locations, dorsoven-
trally. All morphometric analyses were performed blinded to the
genotype of the embryos.
Surface rendering. Surface rendered images of whole embryos
and internal organs were obtained using Amira (Amira 2019.3,
ThermoFisher Scientific, US). Rendering was performed on
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module of Amira was used to illustrate the segmentation and
surface rendering processes (Supplementary Material, Movie 1).
Histology
Cryotomy. Prior to sectioning, whole embryos from a single
litter were dissected and fixed in 4% PFA overnight at 4◦C. They
were then left in a PBS-30% sucrose solution overnight and
embedded in cryomolds using a 1:1 30% sucrose-OCT compound
solution (embedding medium, VWR, US). Using a cryostat, all
20 μm thick transverse sections of the whole embryos were
collected on SuperfrostTMPlus slides (ThermoFisher) and kept at
−20◦C prior to routine haematoxylin and eosin staining.
Morphometric measurements. IVS and left ventricular wall thick-
ness were measured on the transverse sections where branching
of the trachea into bronchi could be observed. Each value corre-
sponds to the average length measured across the structure in
three locations, dorsoventrally, from one embryo. Measurements
were taken using Fiji (ImageJ, version 2.0.0). All morphomet-
ric analyses were performed blinded to the genotype of the
embryos.
Proteomics
E14.5 embryos from three different litters were individually dis-
sected to collect spinal cord (ventral part) and brain cleaned of
all meninges, as well as liver, heart and a sample of abdominal
skeletal muscle. All samples were snap frozen on dry ice and
then stored at −80◦C prior to protein extraction. We used five
SMA and five control samples pooled together for each organ,
coming from these three litters.
Protein extraction. Individual organs were resuspended in
label-free lysis buffer (100 nM Tris–HCl pH = 7.6, 4% (w/v) SDS)
supplemented with 1 × EDTA-free protease inhibitor cocktail
(ThermoFisher Scientific). The tissues were homogenized using
GentleMACSTM M-Tubes on the protein run of the GentleMACSTM
tissue dissociator (Miltenyi Biotech Inc., Germany). After transfer
to Eppendorfs and centrifugation at 200 000 g for 20 min, the
protein-containing supernatant was transferred to low-binding
tubes and stored at −80◦C.
Quality controls. All individual samples were quantified for
protein concentration using a BCA assay and following man-
ufacturer’s instructions (PierceTM BCA Protein Assay Kit, Ther-
moFisher Scientific). To check for accurate quantification and
sample integrity, for every sample, 5 μg of protein mixed with
NuPAGETM SDS sample buffer (4×, ThermoFisher) was loaded
into the wells of an NuPAGE 4–12% Tris-Bis gel. After elec-
trophoresis, the gels stained overnight at room temperature with
InstantBlueTM total protein stain. The gels were then imaged
using an infrared scanner (Odyssey LI-COR biosciences, US) at
700 nm and analyzed using ImageStudioTM Lite (LI-COR). After
subtraction of background signal, fluorescence intensity was
measured for each sample on the totality of the lane and on three
arbitrarily chosen regions (198–62, 62–28 and 28–6 kDa) (45).
Pooling. For each organ, two pools were made, control and
SMA, with each pool comprising of 25 μg of protein from five
individual embryos. Quality controls were then performed on
each of the 10 pools using BCA assays and total protein stains as
described above (3 μg per pool were used for the electrophoresis.)
Mass spectrometry. The samples were processed for 10-plex
TMT mass spectrometry at the FingerPrints Proteomics facility
in Dundee, as previously described (46,47).
Data analysis. Filtered protein IDs were inputted into the
IPA application (Ingenuity Systems, Silicon Valley, CA), which
returned a set of mapped IDs, which were further sorted into
significantly affected proteins based on a threshold of 20% of
up- or downregulation (referred to as dysregulated proteins).
A core analysis performed by IPA associates protein IDs in the
Ingenuity’s Knowledge Database to identify affected canonical
pathways. IPA returns a ratio of the number of molecules in
the dataset per pathway and the total number of molecules that
map to that pathway. To rank the top 100 most affected canonical
pathways for each organ, we used the second value returned by
IPA: the P-value of Fisher’s exact test (shown as -log(P-value)).
Further computational analyses were performed in RStudio
(version 1.2.1335) and GraphPad Prism (version 8.2.0). For protein
overlap in absolute and percentage numbers, overlapping lists
of proteins across two, three and four organs were extracted
from Venny 2.1.0 (http://bioinfogp.cnb.csic.es/tools/venny/) and
from IPA for all five organs. Bar charts were plotted in GraphPad
and assembled in Affinity Designer (version 1.7.3) using the
UpSet’s layout for visualization of intersections (48). Heatmaps
for canonical pathways were built using the gplots library in
RStudio. More information on the methodology behind IPA can
be found at http://ingenuity.com/.
Further functional analyses on the differentially expressed
proteins were performed using the DAVID, version 6.8, avail-
able at https://david.ncifcrf.gov/home.jsp. DAVID uses Fisher’s
exact test to calculate P-values for protein enrichment scores.
Enrichment for proteins in described categories was considered
significant for Benjamini-corrected P-values <0.05 (49,50).
Western blot
The samples used for proteomics were pooled again for quanti-
tative western blotting. The same quantity of protein was used
from each individually extracted sample. Pools were prepared for
western blotting by adding 4 × SDS sample buffer containing β-
mercaptoethanol (Sigma-Aldrich). For all pools, 10 μg of protein
was loaded onto a 4–12% Bis-Tris gradient gel (ThermoFisher
Scientific). The rest of the procedure followed what has been
previously described (33,34). After transfer, membranes were
incubated in Revert Total Protein Stain (LI-COR) for 1 h at room
temperature, washed 2 × 5 min in Revert Total Protein wash
solution (LI-COR) and 1 × 5 min in MilliQ water before blocking
with Odyssey PBS blocking buffer (LI-COR) for 30 min at room
temperature. Membranes were incubated overnight with 1:500
mouse anti-SMN antibody (BD bioscience 610 646) in blocking
buffer. Membranes were then washed 3 × 10 min in PBS prior to
incubation for 1 h at room temperature with a 1:5000 secondary
antibody (donkey-anti-mouse IRDye 800, LI-COR) in blocking
buffer. Membranes were washed 3 × 30 min in PBS, dried and
imaged on an Odyssey CLX laser-based scanning system (LI-
COR). Quantification was performed according to Groen et al.
(32), by normalizing the SMN signal with the total protein stain
signal of each lane.
Statistics
Statistical analyses were performed in GraphPad Prism (version
8.2.0) using unpaired t-tests (significance ∗P < 0.05, ∗∗P < 0.01) for
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Data availability
The raw proteomics data supporting the conclusions of this
article are available in the University of Edinburgh DataShare
repository, https://doi.org/10.7488/ds/2776.
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